Clinical Trial Update: Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated adding ofatumumab to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia, and the study status indicate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Brno University Hospital | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED